Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 8/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545717 | 0.91 | CNR1 (0.49) | CNR1CNR2LIPEMETNAMPT | |
| SCHEMBL5516071 | 0.91 | CNR1 (0.56) | CNR1CNR2DPP4LIPEMET | |
| SCHEMBL14545701 | 0.90 | CNR1 (0.56) | CNR1CNR2LIPEMETNAMPT | |
| SCHEMBL14523449 | 0.89 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL14545423 | 0.84 | CNR1 (0.53) | CNR1CNR2DPP4PIK3CD | |
| SCHEMBL5519690 | 0.84 | CNR1 (0.53) | CNR1CNR2DPP4METPIK3CD | |
| SCHEMBL14545099 | 0.83 | CNR1 (0.57) | CNR1CNR2LIPENAMPTPIK3CD | |
| SCHEMBL14523450 | 0.82 | CNR1 (0.52) | CNR1CNR2PIK3CD | |
| SCHEMBL4691295 | 0.82 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL14545420 | 0.81 | CNR1 (0.51) | CNR1CNR2LIPENAMPTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885DPP4 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.